{
    "name": "pertuzumab/trastuzumab/hyaluronidase",
    "comment": "Rx",
    "other_names": [
        "Phesgo",
        "pertuzumab-trastuzumab-hyaluronidase-zzxf"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-HER2"
    ],
    "source": "https://reference.medscape.com/drug/phesgo-pertuzumab-trastuzumab-hyaluronidase-4000084",
    "pregnancy": {
        "common": [
            "May cause fetal harm when administered to a pregnant female",
            "In postmarketing reports, use of IV trastuzumab during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death",
            "Verify pregnancy status of females of reproductive potential before initiation"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "  ",
                    "  ",
                    "In an animal reproduction study, administration of pertuzumab to pregnant cynomolgus monkeys during organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryofetal deaths at clinically relevant exposures that were 2.5- to 20-fold greater than exposures in humans receiving the recommended dose, based on peak plasma concentration",
                    "  ",
                    "  ",
                    "In studies in which IV trastuzumab was administered to pregnant cynomolgus monkeys during organogenesis at doses up to 25 mg/kg given twice weekly (up to 25x the recommended weekly human dose of 2 mg/kg), trastuzumab crossed the placental barrier during the early (gestation days 20 to 50) and late (gestation days 120 to 150) phases of gestation"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 7 months after the last dose"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Monitor females who received treatment during pregnancy or within 7 months prior to conception for oligohydramnios",
                    "If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care"
                ]
            },
            {
                "type": "Pregnancy pharmacovigilance program",
                "description": [
                    "If administered during pregnancy, or if a patient becomes pregnant during treatment or within 7 months following the last dose, healthcare providers and patients should immediately report exposure to Genentech at 1-888-835-2555"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No information available on the presence of pertuzumab, trastuzumab, or hyaluronidase in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Published data suggest that human IgG is present in human milk but does not enter the neonatal and infant circulation in substantial amounts",
            "Trastuzumab was present in the milk of lactating cynomolgus monkeys but was not associated with neonatal toxicity",
            "Take into account that the elimination half-life of pertuzumab and trastuzumab washout period is 7 months when considering the motherâ€™s clinical need for treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cardiomyopathy",
                    "description": [
                        "Administration can result in subclinical and clinical cardiac failure",
                        "Incidence and severity was highest in patients receiving Phesgo with anthracycline-containing chemotherapy regimens",
                        "Evaluate cardiac function before and during treatment",
                        "Discontinue Phesgo in patients receiving adjuvant therapy and withhold in patients with metastatic disease for clinically significant decrease in LVEF"
                    ]
                },
                {
                    "type": "Embryofetal toxicity",
                    "description": [
                        "Exposure to Phesgo can result in embryofetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death",
                        "Advise patients of these risks and the need for effective contraception"
                    ]
                },
                {
                    "type": "Pulmonary toxicity ",
                    "description": [
                        "Administration can result in serious and fatal pulmonary toxicity",
                        "Discontinue for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome; monitor until symptoms completely resolve"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any of its excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, and cardiac death may occur",
                "May cause fetal harm when administered to a pregnant female",
                "Serious and fatal pulmonary toxicity reported",
                "May cause exacerbation of chemotherapy-induced neutropenia",
                "Severe administration-related reactions, including hypersensitivity, anaphylaxis, and events with fatal outcomes, have been associated with IV pertuzumab and trastuzumab"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Patients who receive anthracycline after stopping Phesgo may be at increased risk of cardiac dysfunction because of the long washout period of Phesgo",
                        "If possible, avoid anthracycline-based therapy for up to 7 months after stopping Phesgo",
                        "If anthracyclines are used, carefully monitor cardiac function"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "trastuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "beclomethasone, inhaled",
            "description": {
                "common": "beclomethasone, inhaled will decrease the level or effect of hyaluronidase by  unspecified interaction mechanism. Avoid or Use Alternate Drug. Larger hyaluronidase doses may be required to achieve desired effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "trastuzumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of pertuzumab by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abatacept",
            "description": {
                "common": "trastuzumab, abatacept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abemaciclib",
            "description": {
                "common": "trastuzumab, abemaciclib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "trastuzumab, acalabrutinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ado-trastuzumab emtansine",
            "description": {
                "common": "trastuzumab, ado-trastuzumab emtansine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alemtuzumab",
            "description": {
                "common": "trastuzumab, alemtuzumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "hyaluronidase, alprazolam. Other (see comment). Use Caution/Monitor. \nComment: Drug combination has been found to be incompatible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anakinra",
            "description": {
                "common": "trastuzumab, anakinra.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "trastuzumab, antithymocyte globulin equine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "trastuzumab, antithymocyte globulin rabbit.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "articaine",
            "description": {
                "common": "hyaluronidase, articaine. Other (see comment). Use Caution/Monitor. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Salicylates, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "aspirin rectal decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Salicylates, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Salicylates, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azacitidine",
            "description": {
                "common": "trastuzumab, azacitidine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azathioprine",
            "description": {
                "common": "trastuzumab, azathioprine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azelastine",
            "description": {
                "common": "azelastine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "baricitinib",
            "description": {
                "common": "trastuzumab, baricitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "basiliximab",
            "description": {
                "common": "trastuzumab, basiliximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "bazedoxifene/conjugated estrogens decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Enhanced tissue resistance to hyaluronidase."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beclomethasone, inhaled",
            "description": {
                "common": "trastuzumab, beclomethasone, inhaled.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beclomethasone, intranasal",
            "description": {
                "common": "trastuzumab, beclomethasone, intranasal.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "trastuzumab, belatacept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belimumab",
            "description": {
                "common": "trastuzumab, belimumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betamethasone",
            "description": {
                "common": "trastuzumab, betamethasone.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bleomycin",
            "description": {
                "common": "trastuzumab, bleomycin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "blinatumomab",
            "description": {
                "common": "trastuzumab, blinatumomab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brentuximab vedotin",
            "description": {
                "common": "trastuzumab, brentuximab vedotin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brodalumab",
            "description": {
                "common": "trastuzumab, brodalumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brompheniramine",
            "description": {
                "common": "brompheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "trastuzumab, budesonide.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "busulfan",
            "description": {
                "common": "trastuzumab, busulfan.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "trastuzumab, cabazitaxel.\nEither increases levels of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "canakinumab",
            "description": {
                "common": "trastuzumab, canakinumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capecitabine",
            "description": {
                "common": "trastuzumab, capecitabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbinoxamine",
            "description": {
                "common": "carbinoxamine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "trastuzumab, carboplatin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carmustine",
            "description": {
                "common": "trastuzumab, carmustine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "trastuzumab, certolizumab pegol.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cetirizine",
            "description": {
                "common": "cetirizine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "trastuzumab, chlorambucil.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroprocaine",
            "description": {
                "common": "hyaluronidase, chloroprocaine. Other (see comment). Use Caution/Monitor. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpheniramine",
            "description": {
                "common": "chlorpheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "pertuzumab decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "choline magnesium trisalicylate decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Salicylates, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "trastuzumab, cisplatin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cladribine",
            "description": {
                "common": "trastuzumab, cladribine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clemastine",
            "description": {
                "common": "clemastine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clofarabine",
            "description": {
                "common": "trastuzumab, clofarabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "hyaluronidase, clonazepam. Other (see comment). Use Caution/Monitor. \nComment: Drug combination has been found to be incompatible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "conjugated estrogens decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Enhanced tissue resistance to hyaluronidase."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "conjugated estrogens, vaginal decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Enhanced tissue resistance to hyaluronidase."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "copanlisib",
            "description": {
                "common": "trastuzumab, copanlisib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "corticotropin",
            "description": {
                "common": "corticotropin decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Corticotropin (ACTH), when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Cortisone, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "cyclizine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "trastuzumab, cyclophosphamide.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "trastuzumab, cyclosporine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "cyproheptadine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cytarabine",
            "description": {
                "common": "trastuzumab, cytarabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "trastuzumab, dacarbazine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dactinomycin",
            "description": {
                "common": "trastuzumab, dactinomycin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "trastuzumab, dasatinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daunorubicin",
            "description": {
                "common": "trastuzumab, daunorubicin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "trastuzumab, deflazacort.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "pertuzumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "trastuzumab, dexamethasone.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and pertuzumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bupivacaine",
            "description": {
                "common": "hyaluronidase, bupivacaine. Other (see comment). Minor/Significance Unknown. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mepivacaine",
            "description": {
                "common": "hyaluronidase, mepivacaine. Other (see comment). Minor/Significance Unknown. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic.  This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prilocaine",
            "description": {
                "common": "hyaluronidase, prilocaine. Other (see comment). Minor/Significance Unknown. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ropivacaine",
            "description": {
                "common": "hyaluronidase, ropivacaine. Other (see comment). Minor/Significance Unknown. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Low hemoglobin",
            "percent": "90"
        },
        {
            "name": "Low absolute lymphocytes",
            "percent": "89"
        },
        {
            "name": "High creatinine",
            "percent": "84"
        },
        {
            "name": "Low total leukocytes",
            "percent": "82"
        },
        {
            "name": "Alopecia",
            "percent": "77"
        },
        {
            "name": "Low total absolute neutrophils",
            "percent": "68"
        },
        {
            "name": "Nausea",
            "percent": "60"
        },
        {
            "name": "Diarrhea",
            "percent": "60"
        },
        {
            "name": "High ALT",
            "percent": "58"
        },
        {
            "name": "High AST",
            "percent": "50"
        },
        {
            "name": "Anemia",
            "percent": "36"
        },
        {
            "name": "Asthenia",
            "percent": "31"
        },
        {
            "name": "Fatigue",
            "percent": "29"
        },
        {
            "name": "Low platelets",
            "percent": "27"
        },
        {
            "name": "Stomatitis",
            "percent": "25"
        },
        {
            "name": "Myalgia",
            "percent": "25"
        },
        {
            "name": "Arthralgia",
            "percent": "24"
        },
        {
            "name": "Constipation",
            "percent": "22"
        },
        {
            "name": "Neutropenia",
            "percent": "22"
        },
        {
            "name": "Vomiting",
            "percent": "20"
        },
        {
            "name": "Radiation skin injury",
            "percent": "19"
        },
        {
            "name": "Decreased appetite",
            "percent": "17"
        },
        {
            "name": "Dysgeusia",
            "percent": "17"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Insomnia",
            "percent": "17"
        },
        {
            "name": "Low potassium",
            "percent": "17"
        },
        {
            "name": "Low albumin",
            "percent": "16"
        },
        {
            "name": "Peripheral sensory neuropathy",
            "percent": "16"
        },
        {
            "name": "Rash",
            "percent": "16"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "15"
        },
        {
            "name": "Injection site reaction",
            "percent": "15"
        },
        {
            "name": "Dry skin",
            "percent": "15"
        },
        {
            "name": "Cough",
            "percent": "15"
        },
        {
            "name": "Dyspepsia",
            "percent": "14"
        },
        {
            "name": "Pyrexia",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "13"
        },
        {
            "name": "Procedural pain",
            "percent": "13"
        },
        {
            "name": "High potassium",
            "percent": "13"
        },
        {
            "name": "Low sodium",
            "percent": "13"
        },
        {
            "name": "Epistaxis",
            "percent": "12"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "12"
        },
        {
            "name": "Hot flush",
            "percent": "12"
        },
        {
            "name": "Decreased weight",
            "percent": "11"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "11"
        },
        {
            "name": "Low absolute lymphocytes",
            "percent": "37"
        },
        {
            "name": "Low total absolute neutrophils",
            "percent": "30"
        },
        {
            "name": "Low total leukocytes",
            "percent": "25"
        },
        {
            "name": "Neutropenia",
            "percent": "14"
        },
        {
            "name": "Paresthesia",
            "percent": "10"
        },
        {
            "name": "Back pain",
            "percent": "10"
        },
        {
            "name": "High bilirubin",
            "percent": "9"
        },
        {
            "name": "Low glucose",
            "percent": "9"
        },
        {
            "name": "Nail discoloration",
            "percent": "9"
        },
        {
            "name": "Erythema",
            "percent": "9"
        },
        {
            "name": "Hemorrhoids",
            "percent": "9"
        },
        {
            "name": "Abdominal pain",
            "percent": "9"
        },
        {
            "name": "Leukopenia",
            "percent": "9"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "8"
        },
        {
            "name": "Peripheral edema",
            "percent": "8"
        },
        {
            "name": "High sodium",
            "percent": "7"
        },
        {
            "name": "Malaise",
            "percent": "7"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "7"
        },
        {
            "name": "Dermatitis",
            "percent": "7"
        },
        {
            "name": "Nail disorder",
            "percent": "7"
        },
        {
            "name": "Bone pain",
            "percent": "7"
        },
        {
            "name": "Pain in extremity",
            "percent": "6"
        },
        {
            "name": "Muscle spasms",
            "percent": "6"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "6"
        },
        {
            "name": "Palmoplantar erythrodysesthesia syndrome",
            "percent": "6"
        },
        {
            "name": "Influenza",
            "percent": "5"
        },
        {
            "name": "like illness",
            "percent": "7"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "7"
        },
        {
            "name": "Diarrhea",
            "percent": "5.2"
        },
        {
            "name": "Low potassium",
            "percent": "2.8"
        },
        {
            "name": "Low hemoglobin",
            "percent": "2.4"
        },
        {
            "name": "Leukopenia",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Nausea",
            "percent": "1.6"
        },
        {
            "name": "Anemia",
            "percent": "1.6"
        },
        {
            "name": "High ALT",
            "percent": "1.6"
        },
        {
            "name": "Hypokalemia",
            "percent": "1.2"
        },
        {
            "name": "High potassium",
            "percent": "1.2"
        },
        {
            "name": "Dyspnea",
            "percent": "0.8"
        },
        {
            "name": "High sodium",
            "percent": "0.8"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "0.8"
        },
        {
            "name": "High AST",
            "percent": "0.8"
        },
        {
            "name": "Decreased appetite",
            "percent": "0.8"
        },
        {
            "name": "Decreased weight",
            "percent": "0.8"
        },
        {
            "name": "Paresthesia",
            "percent": "0.8"
        },
        {
            "name": "Peripheral sensory neuropathy",
            "percent": "0.8"
        },
        {
            "name": "Vomiting",
            "percent": "0.8"
        },
        {
            "name": "Stomatitis",
            "percent": "0.8"
        },
        {
            "name": "Palmoplantar erythrodysesthesia syndrome",
            "percent": "0.4"
        },
        {
            "name": "Asthenia",
            "percent": "0.4"
        },
        {
            "name": "Abdominal pain",
            "percent": "0.4"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "0.4"
        },
        {
            "name": "Low sodium",
            "percent": "0.4"
        },
        {
            "name": "Lacrimation increased",
            "percent": "0.4"
        },
        {
            "name": "Dry eye",
            "percent": "0.4"
        },
        {
            "name": "Radiation skin injury",
            "percent": "0.4"
        },
        {
            "name": "Paronychia",
            "percent": "0.4"
        },
        {
            "name": "Urinary tract infection",
            "percent": "0.4"
        },
        {
            "name": "Cough",
            "percent": "0.4"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "0.4"
        },
        {
            "name": "Myalgia",
            "percent": "0.4"
        },
        {
            "name": "Dry skin",
            "percent": "0.4"
        },
        {
            "name": "Rash",
            "percent": null
        }
    ]
}